Aspen Neuroscience, Inc. (ASPE)
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Aspen Neuroscience Inc.
NASDAQ:ASPEHealthcare · Biotechnology
PrePre-market-3.16%$14.42
Close$14.89AH$14.72-2.04%since
Mkt Cap$432.98M
Float17.82M
O/S29.08M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Pipeline1 lead-sponsored trial·1 active0 completed
Trials need funding. See this company's dilution risk and cash position.
Clinical Trials
- Phase 1Enrolling by invitation
Phase 1/2a Study of ANPD001 in Parkinson Disease
ANPD001
Parkinson Disease
NCT06344026Enrollment9StartJan 2024Primary CompletionMar 2027est.CompletionApr 2030est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1 | Enrolling by invitation | ANPD001 | NCT06344026 |